Replicating viral vectors as HIV vaccines: Summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference

Biologicals

Volumn 38, Issue 4, 2010, Pages 511-521

  Excler, J L ^a   Parks, C L ^a   Ackland, J ^b   Rees, H ^c   Gust, I D ^d   Koff, W C ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Global BioSolutions   (Australia)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Accelerating the development of replicating viral vectors; Advancement of HIV vaccines; AIDS Vaccines; Novel replication competent viral vectors; Replicating viral vectors; Vaccine 2009 Conference Paris

Indexed keywords

ADENOVIRUS VECTOR; DENGUE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SMALLPOX VACCINE; VIRUS VECTOR;

CANINE DISTEMPER MORBILLIVIRUS; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS; DENGUE; DRUG EFFICACY; DRUG SAFETY; GENETIC IMMUNIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SMALLPOX; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS VIRULENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HIV INFECTIONS; HUMANS; RESEARCH REPORT; VIRUS REPLICATION;

EID: 77955272708     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2010.03.005     Document Type: Conference Paper

References (142)

1. Unaids, Who. AIDS epidemic update: November 2009. In: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization UNAIDS-(WHO) 2009; 2009.
2. Johnston M.I., Fauci A.S. An HIV vaccine - challenges and prospects. N Engl J Med 2008, 359:888-890.
3. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
4. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
5. Berkley S.F., Koff W.C. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007, 370:94-101.
6. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
7. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7:19-23.
8. Koff W.C., Parks C.L., Berkhout B., Ackland J., Noble S., Gust I.D. Replicating viral vectors as HIV vaccines summary report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference, July 22, 2007. Biologicals 2008, 36:277-286.
9. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18:546-556.
10. EMEA Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines 2009, European Medicines Regulatory Agency, London.
11. Barrett T. Morbillivirus infections, with special emphasis on morbilliviruses of carnivores. Vet Microbiol 1999, 69:3-13.
12. Beineke A., Puff C., Seehusen F., Baumgartner W. Pathogenesis and immunopathology of systemic and nervous canine distemper. Vet Immunol Immunopathol 2009, 127:1-18.
13. Pillet S., Svitek N., von Messling V. Ferrets as a model for morbillivirus pathogenesis, complications, and vaccines. Curr Top Microbiol Immunol 2009, 330:73-87.
14. Rima B.K., Duprex W.P. Morbilliviruses and human disease. J Pathol 2006, 208:199-214.
15. Appel M.J. Distemper pathogenesis in dogs. J Am Vet Med Assoc 1970, 156:1681-1684.
16. Sips G.J., Chesik D., Glazenburg L., Wilschut J., De Keyser J., Wilczak N. Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Rev Med Virol 2007, 17:223-244.
17. Summers B.A., Appel M.J. Aspects of canine distemper virus and measles virus encephalomyelitis. Neuropathol Appl Neurobiol 1994, 20:525-534.
18. Chappuis G. Control of canine distemper. Vet Microbiol 1995, 44:351-358.
19. Christe K.L., McChesney M.B., Spinner A., Rosenthal A.N., Allen P.C., Valverde C.R., et al. Comparative efficacy of a canine distemper-measles and a standard measles vaccine for immunization of rhesus macaques (Macaca mulatta). Comp Med 2002, 52:467-472.
20. Hoekenga M.T., Schwarz A.J. Carrizo Palma H, Boyer PA. Experimental vaccination against measles. II. Tests of live measles and live distemper vaccine in human volunteers during a measles epidemic in Panama. J Am Med Assoc 1960, 173:868-872.
21. Lin J., Calcedo R., Vandenberghe L.H., Figueredo J.M., Wilson J.M. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 2008, 19:663-669.
22. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 2001, 82:2215-2223.
23. Giraudon P., Wild T.F. Differentiation of measles virus strains and a strain of canine distemper virus by monoclonal antibodies. J Gen Virol 1981, 57:179-183.
24. Giraudon P., Wild T.F. Monoclonal antibodies against measles virus. J Gen Virol 1981, 54:325-332.
25. DeLay P.D., Stone S.S., Karzon D.T., Katz S., Enders J. Clinical and immune response of alien hosts to inoculation with measles, rinderpest, and canine distemper viruses. Am J Vet Res 1965, 26:1359-1373.
26. Taylor J., Pincus S., Tartaglia J., Richardson C., Alkhatib G., Briedis D., et al. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol 1991, 65:4263-4274.
27. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
28. Bhamarapravati N., Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18(Suppl 2):44-47.
29. Kanesa-Thasan N., Edelman R., Tacket C.O., Wasserman S.S., Vaughn D.W., Coster T.S., et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003, 69:17-23.
30. Kanesa-thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19:3179-3188.
31. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66:264-272.
32. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25:2941-2950.
33. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004, 78:1032-1038.
34. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80:302-311.
35. WHO Guidelines for production and quality control of candidate tetravalent dengue virus vaccines (live). WHO Technical Report Series 2006, vol. 932. Geneva, pp. 43-72.
36. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33:131-144.
37. Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K., Nichols R., et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol 2004, 78:9998-10008.
38. Lefeuvre A., Contamin H., Decelle T., Fournier C., Lang J., Deubel V., et al. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. Microbes Infect 2006, 8:1530-1538.
39. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298:146-159.
40. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 2009, 27:505-512.
41. Guy B., Chanthavanich P., Gimenez S., Sirivichayakul C., Sabchareon A., Begue S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004, 22:3563-3574.
42. Mantel N., Aguirre M., Gulia S., Girerd-Chambaz Y., Colombani S., Moste C., et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008, 151:40-46.
43. Johnson B.W., Chambers T.V., Crabtree M.B., Bhatt T.R., Guirakhoo F., Monath T.P., et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 2002, 67:260-265.
44. McGee C.E., Tsetsarkin K., Vanlandingham D.L., McElroy K.L., Lang J., Guy B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008, 197:686-692.
45. McGee C.E., Lewis M.G., Claire M.S., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008, 197:693-697.
46. Fang Q., Yang L., Zhu W., Liu L., Wang H., Yu W., et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005, 335:242-251.
47. Feery B.J. Adverse reactions after smallpox vaccination. Med J Aust 1977, 2:180-183.
48. Gu S.Y., Huang T.M., Ruan L., Miao Y.H., Lu H., Chu C.M., et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995, 84:171-177.
49. Liu G.Q., Cao X., Zhu J.M., Ren G.F., Li H.M., Xie Y.X., et al. Selection of recombinant vaccinia viruses (Tian Tan strain) expressing hepatitis B virus surface antigen by using beta-galactosidase as a marker. Sci China B 1990, 33:188-197.
50. Qiu Z., Xing H., Wei M., Duan Y., Zhao Q., Xu J., et al. Characterization of five nearly full-length genomes of early HIV type 1 strains in Ruili city: implications for the genesis of CRF07_BC and CRF08_BC circulating in China. AIDS Res Hum Retroviruses 2005, 21:1051-1056.
51. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004, 43:1503-1510.
52. Dai K., Liu Y., Liu M., Xu J., Huang W., Huang X., et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008, 26:5062-5071.
53. Gorman W.L., Gill D.S., Scroggs R.A., Portner A. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology 1990, 175:211-221.
54. Dave V.P., Allan J.E., Slobod K.S., Smith F.S., Ryan K.W., Takimoto T., et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 1994, 199:376-383.
55. Smith F.S., Portner A., Leggiadro R.J., Turner E.V., Hurwitz J.L. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 1994, 205:453-461.
56. Hurwitz J.L. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J 2008, 27:S126-S128.
57. Jones B., Zhan X., Mishin V., Slobod K.S., Surman S., Russell C.J., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009, 27:1848-1857.
58. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004, 22:3182-3186.
59. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004, 199:1709-1718.
60. Tsukamoto T., Yuasa M., Yamamoto H., Kawada M., Takeda A., Igarashi H., et al. Induction of CD8+ cells able to suppress CCR5-tropic simian immunodeficiency virus SIVmac239 replication by controlled infection of CXCR4-tropic simian-human immunodeficiency virus in vaccinated rhesus macaques. J Virol 2007, 81:11640-11649.
61. Tsukamoto T., Takeda A., Yamamoto T., Yamamoto H., Kawada M., Matano T. Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4 + T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J Virol 2009, 83:9339-9346.
62. Takeda A., Igarashi H., Nakamura H., Kano M., Iida A., Hirata T., et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 2003, 77:9710-9715.
63. Kato M., Igarashi H., Takeda A., Sasaki Y., Nakamura H., Kano M., et al. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 2005, 23:3166-3173.
64. Moriya C., Horiba S., Inoue M., Iida A., Hara H., Shu T., et al. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques. Biochem Biophys Res Commun 2008, 371:850-854.
65. Kano M., Matano T., Kato A., Nakamura H., Takeda A., Suzaki Y., et al. Primary replication of a recombinant Sendai virus vector in macaques. J Gen Virol 2002, 83:1377-1386.
66. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
67. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005, 5:783-792.
68. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
69. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
70. Franchini G. Choosing the right memory T cell for HIV. Nat Med 2009, 15:244-246.
71. Plotkin S.A. Is there a formula for an effective CMV vaccine?. J Clin Virol 2002, 25(Suppl 2):S13-S21.
72. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008, 325:417-470.
73. Pereira L., Maidji E. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 2008, 325:383-395.
74. Rose J.K., Whitt M.A. Rhabdoviridae: the viruses and their replication. Fields virology 2001, vol. 1:1221-1244. Lippincott, Williams and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
75. Clarke D.K., Cooper D., Egan M.A., Hendry R.M., Parks C.L., Udem S.A. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 2006, 28:239-253.
76. Lyles D., Rupprecht C. Rhabdoviridae. Fields virology 2007, vol. 1:1363-1408. Wolters Kluwer, Philadelphia. D.M. Knipe, D.E. Griffin, R.A. Lamb, S.E. Straus, P.M. Howley, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
77. Rodriguez L.L. Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res 2002, 85:211-219.
78. Mead D.G., Ramberg F.B., Besselsen D.G., Mare C.J. Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. Science 2000, 287:485-487.
79. Letchworth G.J., Rodriguez L.L., Del cbarrera J. Vesicular stomatitis. Vet J 1999, 157:239-260.
80. Rose N.F., Roberts A., Buonocore L., Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000, 74:10903-10910.
81. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549.
82. Johnson J.E., Nasar F., Coleman J.W., Price R.E., Javadian A., Draper K., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007, 360:36-49.
83. Cooper D., Wright K.J., Calderon P.C., Guo M., Nasar F., Johnson J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008, 82:207-219.
84. Johnson J.E., Coleman J.W., Kalyan N.K., Calderon P., Wright K.J., Obregon J., et al. In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine 2009, 27:2930-2939.
85. Xu R., Nasar F., Megati S., Luckay A., Lee M., Udem S.A., et al. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques. J Virol 2009, 83:9813-9823.
86. Cheng S.M., Lee S.G., Ronchetti-Blume M., Virk K.P., Mizutani S., Eichberg J.W., et al. Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 1992, 66:6721-6727.
87. Zhou Q., Hidajat R., Peng B., Venzon D., Aldrich M.K., Richardson E., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5 hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007, 25:8021-8035.
88. Bogers W.M., Davis D., Baak I., Kan E., Hofman S., Sun Y., et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008, 382:217-225.
89. Gomez-Roman V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005, 174:2185-2189.
90. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 81:3414-3427.
91. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009, 182:3718-3727.
92. Patterson L.J., Beal J., Demberg T., Florese R.H., Malkevich N., Venzon D., et al. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008, 374:322-337.
93. Forthal D.N., Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods 1998, 220:129-138.
94. Forthal D.N., Landucci G., Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961.
95. Forthal D.N., Landucci G., Cole K.S., Marthas M., Becerra J.C., Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006, 80:9217-9225.
96. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007, 178:6596-6603.
97. Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4:388-393.
98. Chung A., Rollman E., Johansson S., Kent S.J., Stratov I. The utility of ADCC responses in HIV infection. Curr HIV Res 2008, 6:515-519.
99. Stoiber H., Soederholm A., Wilflingseder D., Gusenbauer S., Hildgartner A., Dierich M.P. Complement and antibodies: a dangerous liaison in HIV infection?. Vaccine 2008, 26(Suppl 8):I79-I85.
100. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004, 78:2212-2221.
101. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8 + T cell responses. Virology 2006, 353:83-98.
102. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83:8300-8314.
103. Ludwig S.L., Brundage J.F., Kelley P.W., Nang R., Towle C., Schnurr D.P., et al. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 1998, 178:1776-1778.
104. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005, 79:2678-2688.
105. Huang X., Lu B., Yu W., Fang Q., Liu L., Zhuang K., et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 2009, 4:e4180.
106. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A 2004, 101:13026-13031.
107. Murphy B.R., Morens D.M., Simonsen L., Chanock R.M., La Montagne J.R., Kapikian A.Z. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003, 187:1301-1308.
108. IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva. Biologicals 2006, 34:233-236.
109. Wilson C.B., Marcuse E.K. Vaccine safety - vaccine benefits: science and the public's perception. Nat Rev Immunol 2001, 1:160-165.
110. Sadoff J.C. Vaccine risk and benefit in the developing world. Health Aff (Millwood) 2005, 24:1379-1380.
111. Milstien J., Cash R.A., Wecker J., Wikler D. Development of priority vaccines for disease-endemic countries: risk and benefit. Health Aff (Millwood) 2005, 24:718-728.
112. Thompson K.M., Tebbens R.J., Pallansch M.A., Kew O.M., Sutter R.W., Aylward R.B., et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 2008, 98:1322-1330.
113. Kempe A., Daley M.F., Parashar U.D., Crane L.A., Beaty B.L., Stokley S., et al. Will pediatricians adopt the new rotavirus vaccine?. Pediatrics 2007, 119:1-10.
114. Widdowson M.A., Steele D., Vojdani J., Wecker J., Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009, 200(Suppl 1):S1-S8.
115. Chen R., Excler J.L., Laderoute M., Mahy B., Hendry R.M., Via C., et al. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG): Maximizing the Comparability and Value of Safety Data from HIV Vaccine Trials. AIDS vaccine 2009. Paris, France 2009.
116. WHO Meeting Report: WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors 2003, World Health Organization, Geneva.
117. Vaccines Roberts L. Rotavirus vaccines' second chance. Science 2004, 305:1890-1893.
118. Kittikraisak W., van Griensven F., Martin M., McNicholl J., Gilbert P.B., Chuachoowong R., et al. Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr 2009, 51:601-608.
119. Benlahrech A., Harris J., Meiser A., Papagatsias T., Hornig J., Hayes P., et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 2009, 106:19940-19945.
120. Sun Y., Bailer R.T., Rao S.S., Mascola J.R., Nabel G.J., Koup R.A., et al. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 2009, 83:10596-10604.
121. Shao Y., Li T., Wolf H., Liu Y., Liu Y., Wang H., et al. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial. Retrovirology 2009, vol. 6. A.L. Ross (Ed.).
122. Yu W., Fang Q., Zhu W., Wang H., Tien P., Zhang L., et al. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge. Vaccine 2009.
123. Jentarra G.M., Heck M.C., Youn J.W., Kibler K., Langland J.O., Baskin C.R., et al. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine 2008, 26:2860-2872.
124. Vijaysri S., Jentarra G., Heck M.C., Mercer A.A., McInnes C.J., Jacobs B.L. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 2008, 26:664-676.
125. Ou Y., Traina-Dorge V., Davis K.A., Gray W.L. Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 2007, 364:291-300.
126. Parker S.D., Rottinghaus S.T., Zajac A.J., Yue L., Hunter E., Whitley R.J., et al. HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine 2007, 25:6764-6773.
127. Samady L., Costigliola E., MacCormac L., McGrath Y., Cleverley S., Lilley C.E., et al. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy. J Virol 2003, 77:3768-3776.
128. Liu B.L., Robinson M., Han Z.Q., Branston R.H., English C., Reay P., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10:292-303.
129. Patterson L.J., Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 2008, 8:1347-1363.
130. Gomez-Roman V.R., Grimes G.J., Potti G.K., Peng B., Demberg T., Gravlin L., et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 2006, 24:5064-5072.
131. Clarke D.K., Nasar F., Lee M., Johnson J.E., Wright K., Calderon P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 2007, 81:2056-2064.
132. Liniger M., Zuniga A., Morin T.N., Combardiere B., Marty R., Wiegand M., et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009, 27:3299-3305.
133. Tangy F., Naim H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 2005, 18:317-326.
134. Combredet C., Labrousse V., Mollet L., Lorin C., Delebecque F., Hurtrel B., et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003, 77:11546-11554.
135. Tangy F., Fećvrier M., Guerbois M., Combredet C., Najburg V., Ruffie C., et al. Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV. AIDS Vaccine 2009. Paris, France 2009.
136. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009, 83:584-597.
137. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8 + T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28:299-308.
138. Bonaldo M.C., Martins M.A., Rudersdorf R., Mudd P.A., Sacha J.B., Piaskowski S.M., et al. Recombinant Yellow Fever Vaccine Virus 17D Expressing SIVmac239 Gag Induces SIV-Specific CD8 + T Cell Responses in Rhesus Macaques. J Virol 2010.
139. Sexton A., De Rose R., Reece J.C., Alcantara S., Loh L., Moffat J.M., et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009, 83:7619-7628.
140. de Goede A.L., Boers P.H., Dekker L.J., Osterhaus A.D., Gruters R.A., Rimmelzwaan G.F. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine 2009, 27:5735-5739.
141. Nakaya Y., Nakaya T., Park M.S., Cros J., Imanishi J., Palese P., et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol 2004, 78:9366-9375.
142. Steinhauer D.A., Langley W.A., Talekar G., Li Z. Novel HIV vaccines using chimeric influenza HA vectors. AIDS Vaccine 2009. Paris, France 2009.